CEACAM1: an adhesion molecule that limits blood-brain barrier damage by neutrophils after stroke.
From the Vascular Biology and Immunopharmacology Group, Department of Pharmacology, Monash University, Clayton, Victoria, Australia.
Christopher G
CG
Sobey
Grant R
GR
Drummond
D000818:Animals; D015703:Antigens, CD / Q000378:metabolism*; D001812:Blood-Brain Barrier / Q000201:enzymology*; D002272:Carcinoembryonic Antigen / Q000378:metabolism*; D015815:Cell Adhesion Molecules / Q000378:metabolism*; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000201:enzymology*; D018836:Inflammation Mediators / Q000378:metabolism*; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D009504:Neutrophils / Q000201:enzymology*
D015703:Antigens, CD; C069847:CD66 antigens; D002272:Carcinoembryonic Antigen; C486183:Ceacam1 protein, mouse; D015815:Cell Adhesion Molecules; D018836:Inflammation Mediators; C579270:MMP9 protein, human; D020780:Matrix Metalloproteinase 9; C501830:Mmp9 protein, mouse
Editorials; blood–brain barrier; inflammation; ischemic stroke; matrix metalloproteinases; neutrophils